Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 03, 2020 / 07:40PM GMT
Release Date Price: $78.76
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

Very welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team. Pleased to introduce from BioMarin, we have Hank Fuchs, President of Worldwide Research and Development; and Brian Mueller, Executive Vice President and Chief Financial Officer. So welcome, Brian, I think you have some interim remarks to make.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO

I do. Thank you, Josh, and thank you all for your interest in BioMarin. 2020 has been an eventful year for us. Developments this year have us set up for more significant updates in 2021. Our next potential product approval will be with vosoritide for the treatment of children with achondroplasia, which is the most common form of dwarfism. Marketing applications in both the United States and Europe are currently under review by health authorities, setting the stage for potential approvals in the second half of 2021.

Vosoritide represents a tremendous

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot